An unresolved question for the understanding of Alzheimer’s disease (AD) pathophysiology
is why a significant percentage of amyloid-β (Aβ)-positive cognitively unimpaired (CU) …

Importance Glial fibrillary acidic protein (GFAP) is a marker of reactive astrogliosis that
increases in the cerebrospinal fluid (CSF) and blood of individuals with Alzheimer disease (AD). …

The quantification of phosphorylated tau in biofluids, either cerebrospinal fluid (CSF) or
plasma, has shown great promise in detecting Alzheimer’s disease (AD) pathophysiology. Tau …

Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …

Whilst cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers for
amyloid-β (Aβ) and tau pathologies are accurate for the diagnosis of Alzheimer’s disease (AD), …

Animal studies suggest that the apolipoprotein E ε4 (APOEε4) allele is a culprit of early
microglial activation in Alzheimer’s disease (AD). Here, we tested the association between …

Background Plasma biomarkers for Alzheimer’s disease (AD) have broad potential as
screening tools in primary care and disease-modifying trials. Detecting elevated amyloid-β (Aβ) …

Introduction Direct comparisons of the main blood phosphorylated tau immunoassays in
memory clinic populations are needed to understand possible differences. Methods In the …

Background Alzheimer’s disease is characterized by an abnormal increase of phosphorylated
tau (pTau) species in the CSF. It has been suggested that emergence of different pTau …

Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer’s
disease are needed to facilitate the initial screening process of participants in disease-…